Business- Page 84

Seasoned biopharmaceutical executive with more than 30 years of leadership experience spanning clinical development, regulatory strategy and operational execution appointed to lead company into new phase of clinical development and growth NEW

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function,

Top Line Growth, Management of Cost and Expenses Drive Strong Third Quarter Q3 GAAP diluted EPS was $1.23 (+39.8% YoY). On a non-GAAP basis, diluted EPS was $1.62 (+47.3% YoY). Profit improvement

Decades of experience growing dual-use defense technology companies  Trusted senior intelligence leader, with a record of accomplishment across strategic, tactical and policy roles Former CEO of Constellis and Tenax Aerospace, global leaders

Trial fully enrolled ahead of schedule Topline data expected in the second half of 2027 WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a

REDWOOD CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”), a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to

Recognition includes three Platinum, five Gold and two Honorable Mention awards spanning brand transformation, integrated marketing, trade show exhibits, influencer marketing, advertising and audio production. METTAWA, Ill. , Nov. 03, 2026 (GLOBE

MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) — Standard Premium Finance Holdings, Inc. (OTCQX: SPFX) (“Standard Premium”), a leading specialty finance company, announces that William (Bill) Koppelmann, CEO, and Brian Krogol, CFO, will